Pub Date : 2024-12-05DOI: 10.1016/j.cpcardiol.2024.102951
Na An , Xiaoyu Zhang , Hongyuan Lin , Qianqian Xu , Qianqian Dai , YiFan Kong , Songjie Han , Xiao Li , Xinyu Yang , Yanwei Xing , Hongcai Shang
Cardio-oncology has emerged as a new translational and clinical field owing to the growing repertory of cancer therapy. To date, there is a lack of effective pharmacological therapy to target cardiotoxicity. Cardio-oncology, which began by investigating the negative effects of cancer medicines on cardiovascular system, has since grown to include research into the similarities between cardiovascular disease (CVD) and cancer. Thioredoxin domain-containing protein 5 (TXNDC5) belongs to the protein disulfide isomerase (PDI) family. Many diseases, including CVD and cancer, improperly express TXNDC5. This review provides a comprehensive analysis of the expression patterns of TXNDC5 in diseases. It outlines the processes via which TXNDC5 contributes to the advancement of malignant diseases such as CVD and cancer. Additionally, it summarizes prospective therapeutic approaches that can be used to target TXNDC5 for the treatment of these diseases. This will offer novel perspectives for enhancing anticancer therapy and advancing cardio-oncology research and drug development.
{"title":"The role and mechanism of TXNDC5 in cardio-oncology: Killing two birds with one stone?","authors":"Na An , Xiaoyu Zhang , Hongyuan Lin , Qianqian Xu , Qianqian Dai , YiFan Kong , Songjie Han , Xiao Li , Xinyu Yang , Yanwei Xing , Hongcai Shang","doi":"10.1016/j.cpcardiol.2024.102951","DOIUrl":"10.1016/j.cpcardiol.2024.102951","url":null,"abstract":"<div><div>Cardio-oncology has emerged as a new translational and clinical field owing to the growing repertory of cancer therapy. To date, there is a lack of effective pharmacological therapy to target cardiotoxicity. Cardio-oncology, which began by investigating the negative effects of cancer medicines on cardiovascular system, has since grown to include research into the similarities between cardiovascular disease (CVD) and cancer. Thioredoxin domain-containing protein 5 (TXNDC5) belongs to the protein disulfide isomerase (PDI) family. Many diseases, including CVD and cancer, improperly express TXNDC5. This review provides a comprehensive analysis of the expression patterns of TXNDC5 in diseases. It outlines the processes via which TXNDC5 contributes to the advancement of malignant diseases such as CVD and cancer. Additionally, it summarizes prospective therapeutic approaches that can be used to target TXNDC5 for the treatment of these diseases. This will offer novel perspectives for enhancing anticancer therapy and advancing cardio-oncology research and drug development.</div></div>","PeriodicalId":51006,"journal":{"name":"Current Problems in Cardiology","volume":"50 3","pages":"Article 102951"},"PeriodicalIF":3.0,"publicationDate":"2024-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142792452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Atrial fibrillation has been linked with poor outcomes in patients with cardiac amyloidosis. We evaluate the in-hospital outcomes of patients with atrial fibrillation and concomitant cardiac amyloidosis with and without catheter ablation.
Methods
The National Inpatient Sample databases (2016 to 2021) were queried to identify patients admitted with atrial fibrillation and concomitant cardiac amyloidosis using ICD 10 codes. The study population aged >18 years was divided into two cohorts; ablation (AB) vs. no ablation (NAB). Multivariate logistic regression model adjusting for baseline characteristics and comorbidities. The primary outcome was all-cause in-hospital mortality. Secondary outcomes were acute heart failure, cardiogenic shock, ventricular fibrillation, major bleeding, stroke, length of stay, and hospitalization cost.
Results
73,160 patients were identified. 595(0.8 %) underwent ablation and 72,656 (99.2 %) did not. Both NAB and AB patients were predominantly white (69.6 % and 60.3 %) respectively. AB patients were younger with median age [74 years (IQR 66-80) vs. 78 years (IQR 71-84), p < 0.01], compared with NAB patients. AB patients were more likely to have heart failure (76.5 % vs. 65.3 %, p = 0.04), and have a family history of CAD (11.1 % vs. 4.8 %, p = 0.03). Contrarily, NAB patients were more likely to have dementia (11.5 % vs. 2.5 %, p = 0.01). After adjusting for baseline characteristics and comorbidity, there was no difference in all-cause mortality (OR 0.3, CI 0.08-1.35, p = 0.12), stroke (OR 1.1, CI 0.4-2.8, p = 0.87), or major bleeding (OR 1.4, CI 0.7-2.6, p = 0.37). Undergoing ablation was associated with higher odds of acute heart failure (OR 1.9, CI 1.1-3.3, p<0.01). After adjusting for inflation using the consumer price index, adjusted total cost of hospitalization was for higher AB patients was compared to NAB patients ($41,499.22 vs. $13,085.11) with a significantly longer length of stay among AB patients (7 days vs. 5days, p < 0.01).
Conclusion
Atrial fibrillation and concomitant cardiac amyloidosis in patients undergoing catheter ablation are associated with an increased risk of acute heart failure, higher cost, and a longer length of stay.
背景：心房颤动与心脏淀粉样变性患者预后不良有关。我们评估心房颤动和合并心脏淀粉样变性患者的住院结果，有和没有导管消融。方法：查询2016 - 2021年全国住院患者样本数据库，使用ICD 10编码识别心房颤动合并心脏淀粉样变性患者。年龄在18岁至18岁之间的研究人群分为两组；消融（AB）与无消融（NAB）。调整基线特征和合并症的多变量logistic回归模型。主要结局为全因住院死亡率。次要结局为大出血、卒中住院时间和住院费用。结果：共发现73,160例患者。595例（0.8%）行消融术，72656例（99.2%）未行消融术。NAB和AB患者均以白人为主（分别为69.6%和60.3%）。AB患者更年轻，中位年龄为74岁（IQR 66-80） vs. 78岁（IQR 71-84）。结论：导管消融患者心房颤动和合并心脏淀粉样变性与急性心力衰竭风险增加、费用增加和住院时间延长相关。
{"title":"Cardiovascular outcomes of patients with atrial fibrillation and concomitant cardiac amyloidosis undergoing percutaneous catheter ablation","authors":"Garba Rimamskep Shamaki MD , Siva Neppala MD , Sinda Hidri MD , Priya Hotwani MD , Mohammed Aldabagh MD , Sundal Aziz MD , Prakash Upreti MD , Amith Seri MBBS , Dilesha Dilangi Kumanayaka MD , Ebenezer Oloyede MD, MPH , Yasar Sattar MD","doi":"10.1016/j.cpcardiol.2024.102953","DOIUrl":"10.1016/j.cpcardiol.2024.102953","url":null,"abstract":"<div><h3>Background</h3><div>Atrial fibrillation has been linked with poor outcomes in patients with cardiac amyloidosis. We evaluate the in-hospital outcomes of patients with atrial fibrillation and concomitant cardiac amyloidosis with and without catheter ablation.</div></div><div><h3>Methods</h3><div>The National Inpatient Sample databases (2016 to 2021) were queried to identify patients admitted with atrial fibrillation and concomitant cardiac amyloidosis using ICD 10 codes. The study population aged >18 years was divided into two cohorts; ablation (AB) vs. no ablation (NAB). Multivariate logistic regression model adjusting for baseline characteristics and comorbidities. The primary outcome was all-cause in-hospital mortality. Secondary outcomes were acute heart failure, cardiogenic shock, ventricular fibrillation, major bleeding, stroke, length of stay, and hospitalization cost.</div></div><div><h3>Results</h3><div>73,160 patients were identified. 595(0.8 %) underwent ablation and 72,656 (99.2 %) did not. Both NAB and AB patients were predominantly white (69.6 % and 60.3 %) respectively. AB patients were younger with median age [74 years (IQR 66-80) vs. 78 years (IQR 71-84), p < 0.01], compared with NAB patients. AB patients were more likely to have heart failure (76.5 % vs. 65.3 %, p = 0.04), and have a family history of CAD (11.1 % vs. 4.8 %, p = 0.03). Contrarily, NAB patients were more likely to have dementia (11.5 % vs. 2.5 %, p = 0.01). After adjusting for baseline characteristics and comorbidity, there was no difference in all-cause mortality (OR 0.3, CI 0.08-1.35, p = 0.12), stroke (OR 1.1, CI 0.4-2.8, p = 0.87), or major bleeding (OR 1.4, CI 0.7-2.6, p = 0.37). Undergoing ablation was associated with higher odds of acute heart failure (OR 1.9, CI 1.1-3.3, p<0.01). After adjusting for inflation using the consumer price index, adjusted total cost of hospitalization was for higher AB patients was compared to NAB patients ($41,499.22 vs. $13,085.11) with a significantly longer length of stay among AB patients (7 days vs. 5days, p < 0.01).</div></div><div><h3>Conclusion</h3><div>Atrial fibrillation and concomitant cardiac amyloidosis in patients undergoing catheter ablation are associated with an increased risk of acute heart failure, higher cost, and a longer length of stay.</div></div>","PeriodicalId":51006,"journal":{"name":"Current Problems in Cardiology","volume":"50 3","pages":"Article 102953"},"PeriodicalIF":3.0,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142781851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-01DOI: 10.1016/j.cpcardiol.2024.102952
Emma Grace Williams , Mohammed Alissa , Mahdi H. Alsugoor , Ghadah Shukri Albakri , Ali A Altamimi , Abdulmajeed Abdulaziz Alabdullateef , Nahlah Makki Almansour , Fahad M. Aldakheel , Salem Alessa , Michael Marber
Atrial fibrillation (AF) is a prevalent clinical arrhythmia associated with a high incidence and severe complications such as cerebral embolism and heart failure. While the etiology and pathogenesis of AF involve numerous factors, recent research emphasizes the significant role of intestinal microbiota imbalance in the emergence and progression of AF, particularly among older adults. This review investigates the mechanisms by which intestinal flora and their metabolites contribute to the onset of AF in the elderly, highlighting novel interactions between gut health and cardiac function. Current literature often overlooks these critical connections, indicating a substantial research gap in understanding how dysbiosis may exacerbate AF and hinder recovery. Furthermore, exploring the bidirectional relationship between the gut microbiome and systemic inflammation in the context of AF provides a unique perspective that has yet to be thoroughly investigated. Future research should focus on longitudinal studies assessing gut microbiota composition and function in AF patients and consider probiotics or prebiotics as potential adjunctive therapies for mitigating AF. This comprehensive approach may pave the way for innovative treatments integrating cardiology with gastroenterology, enhancing patient outcomes through a holistic understanding of health.
{"title":"Integrative approaches to atrial fibrillation prevention and management: Leveraging gut health for improved cardiovascular outcomes in the aging population","authors":"Emma Grace Williams , Mohammed Alissa , Mahdi H. Alsugoor , Ghadah Shukri Albakri , Ali A Altamimi , Abdulmajeed Abdulaziz Alabdullateef , Nahlah Makki Almansour , Fahad M. Aldakheel , Salem Alessa , Michael Marber","doi":"10.1016/j.cpcardiol.2024.102952","DOIUrl":"10.1016/j.cpcardiol.2024.102952","url":null,"abstract":"<div><div>Atrial fibrillation (AF) is a prevalent clinical arrhythmia associated with a high incidence and severe complications such as cerebral embolism and heart failure. While the etiology and pathogenesis of AF involve numerous factors, recent research emphasizes the significant role of intestinal microbiota imbalance in the emergence and progression of AF, particularly among older adults. This review investigates the mechanisms by which intestinal flora and their metabolites contribute to the onset of AF in the elderly, highlighting novel interactions between gut health and cardiac function. Current literature often overlooks these critical connections, indicating a substantial research gap in understanding how dysbiosis may exacerbate AF and hinder recovery. Furthermore, exploring the bidirectional relationship between the gut microbiome and systemic inflammation in the context of AF provides a unique perspective that has yet to be thoroughly investigated. Future research should focus on longitudinal studies assessing gut microbiota composition and function in AF patients and consider probiotics or prebiotics as potential adjunctive therapies for mitigating AF. This comprehensive approach may pave the way for innovative treatments integrating cardiology with gastroenterology, enhancing patient outcomes through a holistic understanding of health.</div></div>","PeriodicalId":51006,"journal":{"name":"Current Problems in Cardiology","volume":"50 3","pages":"Article 102952"},"PeriodicalIF":3.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142774634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-01DOI: 10.1016/j.cpcardiol.2024.102950
Ocílio Ribeiro Gonçalves M.S. , Saul Dominici M.S. , Júlia dos Santos Monteiro M.S. , Elizabet Taylor Pimenta Weba M.S. , Anthony Hong M.S. , Ana Beatriz Santos M.S. , Maria Tereza Camarotti M.S. , Niels Pacheco M.D. , João Victor Araújo de Oliveira M.S. , Arlindo Bispo da Silva Junior M.S. , Márcio Yuri Ferreira M.D. , Kelson James Almeida M.D. Ph.D.
Background
Chagas Disease (CD) poses significant health risks, including an increased incidence of acute ischemic stroke (AIS). However, the specific risk factors for AIS in CD patients are not well-defined. This meta-analysis aims to identify clinically relevant risk factors for AIS in individuals with CD.
Methods
We performed a systematic review and meta-analysis by searching PubMed, Embase, Web of Science, and the Cochrane Library up to August 2024. Primary outcomes evaluated in AIS patients with CD included reduced left ventricular ejection fraction (LVEF), anticoagulation therapy, atrial fibrillation (AF), left ventricular apical aneurysm (LVAA), pacemaker use, and coronary artery disease (CAD). Risk ratios (RRs) and odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using a random-effects model.
Results
Six studies were included, involving 1,229 patients (48% male). The analysis revealed a higher risk of AIS in CD patients with reduced LVEF (RR 3.38; 95% CI 1.38 - 8.27), AF (OR 4.85; 95% CI 2.13 - 11.02), LVAA (OR 3.76; 95% CI 1.96 - 7.21), and pacemaker use (OR 2.37; 95% CI 1.38 - 4.09). Anticoagulation therapy was associated with a reduced likelihood of stroke (OR 0.28; 95% CI 0.19 - 0.41). No significant association was found between CAD and stroke risk (OR 1.56; 95% CI 0.93 - 2.59).
Conclusion
Reduced LVEF, AF, LVAA, and pacemaker use are correlated with higher stroke incidence in CD patients, while anticoagulation therapy diminishes this risk. Further randomized studies are needed to refine AIS prevention strategies for this population.
背景：恰加斯病（CD）具有显著的健康风险，包括急性缺血性卒中（AIS）的发病率增加。然而，乳糜泻患者AIS的具体危险因素尚未明确。本荟萃分析旨在确定cd患者AIS的临床相关危险因素。方法：我们通过检索PubMed， Embase， Web of Science和Cochrane图书馆进行了系统回顾和荟萃分析，截止到2024年8月。评估AIS合并CD患者的主要结局包括左室射血分数（LVEF）降低、抗凝治疗、心房颤动（AF）、左室顶动脉瘤（LVAA）、起搏器使用和冠状动脉疾病（CAD）。采用随机效应模型计算95%置信区间（ci）的风险比（rr）和优势比（ORs）。结果：纳入6项研究，涉及1229例患者（48%为男性）。分析显示，LVEF降低的CD患者发生AIS的风险更高(RR 3.38；95% ci 1.38 - 8.27), af(或4.85；95% ci 2.13 - 11.02), lvaa(或3.76；95% CI 1.96 - 7.21)，起搏器使用(OR 2.37；95% ci 1.38 - 4.09)。抗凝治疗与卒中可能性降低相关(OR 0.28；95% ci 0.19 - 0.41)。冠心病与卒中风险之间没有显著关联(OR 1.56；95% ci 0.93 - 2.59)。结论：降低LVEF、AF、lveaa和使用起搏器与CD患者卒中发生率升高相关，而抗凝治疗可降低这一风险。需要进一步的随机研究来完善针对这一人群的AIS预防策略。
{"title":"Stratifying clinically relevant risk factors for acute ischemic stroke and cerebrovascular events in chagas disease: A systematic review and meta-Analysis","authors":"Ocílio Ribeiro Gonçalves M.S. , Saul Dominici M.S. , Júlia dos Santos Monteiro M.S. , Elizabet Taylor Pimenta Weba M.S. , Anthony Hong M.S. , Ana Beatriz Santos M.S. , Maria Tereza Camarotti M.S. , Niels Pacheco M.D. , João Victor Araújo de Oliveira M.S. , Arlindo Bispo da Silva Junior M.S. , Márcio Yuri Ferreira M.D. , Kelson James Almeida M.D. Ph.D.","doi":"10.1016/j.cpcardiol.2024.102950","DOIUrl":"10.1016/j.cpcardiol.2024.102950","url":null,"abstract":"<div><h3>Background</h3><div>Chagas Disease (CD) poses significant health risks, including an increased incidence of acute ischemic stroke (AIS). However, the specific risk factors for AIS in CD patients are not well-defined. This meta-analysis aims to identify clinically relevant risk factors for AIS in individuals with CD.</div></div><div><h3>Methods</h3><div>We performed a systematic review and meta-analysis by searching PubMed, Embase, Web of Science, and the Cochrane Library up to August 2024. Primary outcomes evaluated in AIS patients with CD included reduced left ventricular ejection fraction (LVEF), anticoagulation therapy, atrial fibrillation (AF), left ventricular apical aneurysm (LVAA), pacemaker use, and coronary artery disease (CAD). Risk ratios (RRs) and odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using a random-effects model.</div></div><div><h3>Results</h3><div>Six studies were included, involving 1,229 patients (48% male). The analysis revealed a higher risk of AIS in CD patients with reduced LVEF (RR 3.38; 95% CI 1.38 - 8.27), AF (OR 4.85; 95% CI 2.13 - 11.02), LVAA (OR 3.76; 95% CI 1.96 - 7.21), and pacemaker use (OR 2.37; 95% CI 1.38 - 4.09). Anticoagulation therapy was associated with a reduced likelihood of stroke (OR 0.28; 95% CI 0.19 - 0.41). No significant association was found between CAD and stroke risk (OR 1.56; 95% CI 0.93 - 2.59).</div></div><div><h3>Conclusion</h3><div>Reduced LVEF, AF, LVAA, and pacemaker use are correlated with higher stroke incidence in CD patients, while anticoagulation therapy diminishes this risk. Further randomized studies are needed to refine AIS prevention strategies for this population.</div></div>","PeriodicalId":51006,"journal":{"name":"Current Problems in Cardiology","volume":"50 3","pages":"Article 102950"},"PeriodicalIF":3.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142774637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-28DOI: 10.1016/j.cpcardiol.2024.102946
Jinfeng Li MD, Lei Bao MD, Mengyue Gu MD, Mengmei Wang MD, Hui Zhong MBBS
Advancements in diagnostic and therapeutic approaches have led to a remarkable reduction in the morbidity and mortality rates associated with a variety of diseases. In the context of acute ischemic heart disease, significant milestones have been achieved, beginning with the establishment of cardiac ICUs. These were pivotal in providing specialized care for patients with severe heart conditions. Subsequent to this development, methods to restore blood flow in areas compromised by arterial blockages were introduced. Initially, systemic thrombolysis was the primary method used, but it has since been largely supplanted by primary percutaneous coronary intervention (PCI), also known as primary coronary angioplasty, which is now the preferred treatment due to its effectiveness and safety. The incidence of out-of-hospital cardiac arrest (OHCA) where resuscitation attempts have been made, whether successful or not, is significant and presents a considerable challenge. Unfortunately, the mortality rate among these patients remains distressingly high, and efforts to reduce it are fraught with difficulty. It is crucial to acknowledge that survival from an OHCA does not automatically equate to a favorable clinical outcome, as serious neurological impairments are common sequelae of such events. In addition to mortality rates, the term "survival with favorable neurologic outcome" has emerged as another critical measure of the success of resuscitation efforts. This parameter underscores the importance of not only saving lives but also preserving the quality of life for survivors. The ability to restore both life and cognitive function is a testament to the comprehensiveness of care provided to OHCA patients.
{"title":"An insight regarding the article ‘Predictors and rate of survival after out-of-hospital cardiac arrest.’","authors":"Jinfeng Li MD, Lei Bao MD, Mengyue Gu MD, Mengmei Wang MD, Hui Zhong MBBS","doi":"10.1016/j.cpcardiol.2024.102946","DOIUrl":"10.1016/j.cpcardiol.2024.102946","url":null,"abstract":"<div><div>Advancements in diagnostic and therapeutic approaches have led to a remarkable reduction in the morbidity and mortality rates associated with a variety of diseases. In the context of acute ischemic heart disease, significant milestones have been achieved, beginning with the establishment of cardiac ICUs. These were pivotal in providing specialized care for patients with severe heart conditions. Subsequent to this development, methods to restore blood flow in areas compromised by arterial blockages were introduced. Initially, systemic thrombolysis was the primary method used, but it has since been largely supplanted by primary percutaneous coronary intervention (PCI), also known as primary coronary angioplasty, which is now the preferred treatment due to its effectiveness and safety. The incidence of out-of-hospital cardiac arrest (OHCA) where resuscitation attempts have been made, whether successful or not, is significant and presents a considerable challenge. Unfortunately, the mortality rate among these patients remains distressingly high, and efforts to reduce it are fraught with difficulty. It is crucial to acknowledge that survival from an OHCA does not automatically equate to a favorable clinical outcome, as serious neurological impairments are common sequelae of such events. In addition to mortality rates, the term \"survival with favorable neurologic outcome\" has emerged as another critical measure of the success of resuscitation efforts. This parameter underscores the importance of not only saving lives but also preserving the quality of life for survivors. The ability to restore both life and cognitive function is a testament to the comprehensiveness of care provided to OHCA patients.</div></div>","PeriodicalId":51006,"journal":{"name":"Current Problems in Cardiology","volume":"50 2","pages":"Article 102946"},"PeriodicalIF":3.0,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142744306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-27DOI: 10.1016/S0146-2806(24)00575-9
{"title":"Information for Readers","authors":"","doi":"10.1016/S0146-2806(24)00575-9","DOIUrl":"10.1016/S0146-2806(24)00575-9","url":null,"abstract":"","PeriodicalId":51006,"journal":{"name":"Current Problems in Cardiology","volume":"50 1","pages":"Article 102940"},"PeriodicalIF":3.0,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142723077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-27DOI: 10.1016/S0146-2806(24)00580-2
{"title":"Guidelines for Authors","authors":"","doi":"10.1016/S0146-2806(24)00580-2","DOIUrl":"10.1016/S0146-2806(24)00580-2","url":null,"abstract":"","PeriodicalId":51006,"journal":{"name":"Current Problems in Cardiology","volume":"50 1","pages":"Article 102945"},"PeriodicalIF":3.0,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142723075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号